Inmune Bio, Inc 8-K, filed Oct 27, 2020
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on October 27, 2020.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2020
| INMUNE BIO INC. | ||
| (Exact name of registrant as specified in charter) |
| Nevada | 001-38793 | 47-5205835 | ||
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
1200 Prospect Street, Suite 525, La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per shares | INMB | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
INmune Bio Inc. (the “Company”) is filing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation.
By filing this Current Report on Form 8-K and furnishing the information
contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be
disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Presentation |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: October 27, 2020 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
2
Exhibit 99.1

www.roth.com Member: FINRA / SIPC 1 of 15 COVID - 19 Review October 2020

www.roth.com Member: FINRA / SIPC 2 of 15 Forward Looking Statements

www.roth.com Member: FINRA / SIPC 3 of 15 Speaker: RJ Tesi MD CEO/CMO Dr . Tesi has been President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015 . Dr . Tesi’s career in medicine and biopaharma has focused on strategies to manipulate the immune system . First, as an academic liver/pancreas/kidney transplant sugeon , he focused on controlling the immune systems attempt to reject life saving organs . While managing immunosuppression on a daily basis, he was introduced to the tricky balance between enough immunosuppression to prevent rejection and too much immunosuppression resulting in life threatening viral infections . In biopharma, his focus has been on controlling the immune response as it relates to disease including autoimmune disease, cancer, neurodegenerative, metabolic and infectious diseases . Dr . Tesi is one of the three founders of INmune Bio, a company focused on reprograming the innate immune system to treat disease . Before his roles at INmune Bio, Dr . Tesi has held senior leadership roles in private and public companies . Dr . Tesi received his medical degree from Washington University in St . Louis and held board certification is general surgery and transplant surgery during his academic career .

www.roth.com Member: FINRA / SIPC 4 of 15 INmune Bio Company Overview Product Platforms • Founded September 2015 • NASDAQ listed (INMB) • Simple capital structure • Multiple clinical programs • Strong IP portfolio • Identifiable near - term catalysts . • DN - TNF platform for treatment dysregulated innate immunity • XPro1595 for Alzheimer’s disease • XPro1595 for Treatment Resistant Depression • Quellor for treatment of COVID19 cytokine storm • INB03 for MUC4 expressing cancers • LIVNate for NASH • INKmune to eliminate minimal residual disease • Treatment of high - risk MDS • Eliminate MRD in CaOva Dark programs are in or soon to be in clinic

www.roth.com Member: FINRA / SIPC 5 of 15 Company Overview Development Platforms • Founded Sept 2015 • NASDAQ: INMB • Simple cap structure • Innate immune system focused • DN - TNF for CNS, immuno - oncology, COVID19 and metabolic diseases • INKmune – an NK cell focused platform targeting minimal residual disease

www.roth.com Member: FINRA / SIPC 6 of 15 Modifying the Catastrophic Complications of COVID19 by targeting the Master Cytokine with Quellor A Phase II trial

What brings patients to the hospital with C19? • Reality #1: At time of admission viral titer is decreasing • Reality #2: The dysregulated innate immune response to the virus causes Cytokine Storm • Problem: Cytokine Storm is making patients sick • Hypothesis: Blunting the effects of Cytokine Storm will alter the arch of the disease • Solution: Target the Master Cytokine of the Cytokine Storm with Quellor Quellor non - confidential October 2020 7

TNF is the “Master Cytokine” • TNF plays an outsize role in Cytokine Storm • sTNF stimulates IL1 and IL6 production • Removal of sTNF from “trio” decreases production of IL1 and IL6 • sTNF and IL1 activate endothelial cells, IL6 does not Quellor non - confidential October 2020 sTNF expression precedes IL1 or IL6 by at least one hour. IL1/IL6 levels blunted in TNF KO mice but not in IL1 KO mice from Rogers Nature 2020 Only TNF blockade decreases CS 8

The ‘3’ pathologies of TNF in COVID - 19 1. Immune cell activation - activated cells produce cytokines 2. Endothelial cell activation – Up - regulation of ICAM/VCAM for transmigration of immune cells from blood vessel to tissue – Up - regulation of Tissue Factor to cause coagulopathy 3. Promotes infection of cells – TNF up - regulates Neurophilin - 1 - both Neurophilin - 1 and ACE2 receptor binding required for COVID19 entry to cell Quellor non - confidential October 2020

Quellor MOA see Steed et al., Science , 301, 2003 Receptor binding, Receptor binding, "small" domain (subunit A) Subunit A Receptor binding, (subunit A) Mutation Y87H (subunit C) Mutation R31C (for 10kD pegylation) "large" domain Subunit C Subunit B Mutation A145R Nonglycosylated small homotrimeric protein expressed in E.coli 10 Quellor non - confidential October 2020 Quellor neutralizes sTNF without effecting tmTNF

Phase I experience - AD • Phase I oncology – ACTRN12618000675 224 – Safe and ↓CRP, CCL2, and IL6 • Phase I AD – NCT03943264 – On - going – reported preliminary data on 6 patients 13 July 2020 Quellor non - confidential October 2020 White Mater Free Water is a biomarker of neuroinflammation Dose response in white matter free water safe mask Decreased neuroinflammation in arcuate fasciculus – a language white matter tract 11

Phase II: Quellor to treat pulmonary complications of C19 • Enrollment criteria: adult COVID19 infection with room air SaO2<94% – High risk comorbidities: age≥60; cardiovascular disease, obesity, diabetes, Black race or Hispanic ethnicity • Treatment groups: Standard - of - Care vs Standard - of - Care + Quellor 1mg/kg subQ on day 1 and 8 (if in hospital) – SOC may include remdesivir and/or dexamethasone 10mg/d (or solumedrol equivalent) End - points: prevent catastrophic complications Quellor non - confidential October 2020 Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ER/Clinic evaluation Day 0 Quellor Day 8 (if in - patient) Quellor Day 1 Standard - of - Care Discharge and out - patient phase Primary end point* day 28 12 * safety evaluation days 40 and 70

www.roth.com Member: FINRA / SIPC 13 of 15